Skip to main content

Table 2 Urinary AGT and renin levels and related factors according to the degree of proteinuria decrement at 24 weeks of valsartan treatment

From: Urinary angiotensinogen as a surrogate marker predicting the antiproteinuric effects of angiotensin receptor blockers in patients with overt proteinuria: a multicenter prospective study

 

Non-decrementa

(n = 152)

Decrementb

(n = 53)

P

Valsartan dose at 24 weeks

  

0.668

 320 mg

96 (63.2%)

31 (58.5%)

 

 160 mg

48 (31.6%)

18 (34.0%)

 

 80 mg

8 (5.3%)

4 (7.5%)

 

Baseline uPCR

1.64 (1.22–2.49)

2.66 (1.84–3.95)

<  0.001

Baseline MAP

111.4 ± 12.0

112.1 ± 12.3

0.713

Baseline ln(uAGT/Cr) (μg/g)

3.29 (2.53–4.21)

3.92 (3.39–4.59)

0.004

Baseline ln(uR/Cr) (pg/g)

−1.25 (−2.11–0.47)

−0.35 (− 1.96–1.73)

0.047

Δln(uAGT/Cr) (μg/g)c

0.00 (−0.79–0.63)

− 0.76 (−2.07–0.80)

< 0.001

  1. Abbreviations: MAP mean arterial pressure, uAGT/Cr urinary angiotensinogen/creatinine ratio, uPCR urinary protein/creatinine ratio, uR/Cr urinary renin/creatinine ratio
  2. aNon-decrement: patients with uPCR decrement < 1 mg/mg
  3. bDecrement: patients with uPCR decrement ≥1 mg/mg
  4. cΔln(uAGT/Cr) = [ln(uAGT/Cr) at 24 weeks] - [baseline ln(uAGT/Cr)]
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us